JAN SKVARKA
Trillium Therapeutics
Trillium Therapeutics
Former President and Chief Executive Officer
Jan Skvarka is Executive Chairman of DEM Biopharma, a discovery stage immuno-oncology company, and GentiBio, a leading pre-clinical stage Tregs cell therapy company focused on auto-immune diseases.
From 2019-21, Jan was the Chief Executive Officer of Trillium Therapeutics (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company. At Trillium, he led a highly successful turn-around, taking a struggling company with a $16M market capitalization to a $2.3B acquisition by Pfizer in two years.
Previously, Jan served as Chief Executive Officer of Tal Medical, a clinical-stage neuroscience company, and a lead partner in the Healthcare Practice at Bain & Company, where he advised leading life sciences companies on strategy, operational improvement and M&A. He started his career in corporate finance with Price Waterhouse in London, UK, and Vienna, Austria. Jan holds an MBA degree from Harvard Business School.
